Higher Single PRX-115 Doses Kept Plasma Uric Acid Levels Below Therapeutic Target for Longer Durations
Protalix BioTherapeutics Presents Data Supporting Potential for Less Frequent Dosing in Phase 2 RELEASE Study for Uncontrolled Gout The Company previously reported that higher single doses of PRX–115 lowered mean plasma uric acid for longer durations in participants with elevated plasma...
Covered in this story
Call it yourself
No calls on $PRX.AS yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Prosus →Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.